Jason Kim named CFO at Enveda

BOULDER — Jason Kim has been appointed chief financial officer at Enveda Biosciences, a biotechnology company using artificial intelligence to translate life’s chemistry into new medicines.

Kim brings more than 20 years of biopharmaceutical corporate development and financial leadership experience to Enveda, whose North American operations are based out of a 60,000-square-foot facility in Boulder’s Flatiron Park business campus.

“We are thrilled to welcome Jason to Enveda,” Viswa Colluru, CEO and founder of Enveda, said in a prepared statement. “His proven track record of driving financial and operational success in the biopharma industry will be key as we scale our operations, expand our pipeline, launch more clinical trials and seek the right partnerships to advance our deep pipeline medicines closer to patients in need.”

Before joining Enveda, Kim served as president, chief operations officer and CFO of Molecular Templates. During his tenure, he successfully raised more than $500 million in equity, strategic partnership and non-dilutive funding. Kim also led the company’s transition to a public entity and strategic collaborations with pharmaceutical companies such as Takeda, Vertex and Bristol Myers Squibb.

Kim’s career also includes leadership roles at ImClone Systems, OSI Pharmaceuticals, Domain Associates and Safeguard Scientifics.

He holds a master’s degree from The Wharton School and a bachelor of arts in neuroscience from Wesleyan University.

“I am excited to join Enveda at such a pivotal time in its journey,” Kim said in a prepared statement. “The company’s innovative 21st century approach to leveraging natural products for drug discovery has tremendous potential to address a huge range of clinical needs. I look forward to working with the talented team at Enveda to drive financial and strategic initiatives that will enable us to deliver on this promise to patients.”

Enveda Biosciences, also known as Enveda Therapeutics Inc., has 10 drug candidates in its development pipeline, including an oral anti-inflammatory therapy for atopic dermatitis that recently began clinical trials.

Founded in 2019, Enveda has raised a total of $360 million from investors.

The company, which wrapped up a $119 million Series B fundraising round in June, has about 250 employees across the globe, including at Enveda’s Asian headquarters in Hyderabad, India.

on Facebook on LinkedIn